Last reviewed · How we verify
Lispro Prandial Insulin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lispro Prandial Insulin (Lispro Prandial Insulin) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lispro Prandial Insulin TARGET | Lispro Prandial Insulin | Eli Lilly and Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lispro Prandial Insulin CI watch — RSS
- Lispro Prandial Insulin CI watch — Atom
- Lispro Prandial Insulin CI watch — JSON
- Lispro Prandial Insulin alone — RSS
Cite this brief
Drug Landscape (2026). Lispro Prandial Insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/lispro-prandial-insulin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing